Not enough known about fenofibrate's kidney effects in people with Type 2 diabetes

FIELD Trial Study Group, Timothy M.E. Davis

Research output: Contribution to journalArticlepeer-review

Abstract

Globally ≈10% of adults have diabetes, with 80% in disadvantaged regions, hence low-cost renoprotective agents are desirable. Fenofibrate demonstrated microvascular benefits in several cardiovascular end-point diabetes trials, but knowledge of effects in late-stage kidney disease is limited. We report new FIELD substudy data and call for further kidney outcomes data.

Original languageEnglish
Article number111612
Number of pages3
JournalDiabetes Research and Clinical Practice
Volume210
DOIs
Publication statusPublished - Apr 2024

Fingerprint

Dive into the research topics of 'Not enough known about fenofibrate's kidney effects in people with Type 2 diabetes'. Together they form a unique fingerprint.

Cite this